SERPINB2 and miR-146a/b are coordinately regulated and act in the suppression of psoriasis-associated inflammatory responses in keratinocytes

Exp Dermatol. 2020 Jan;29(1):51-60. doi: 10.1111/exd.14049. Epub 2019 Nov 13.

Abstract

Psoriasis is a chronic inflammatory skin disease with numerous involved factors. miR-146a and miR-146b (miR-146a/b) are anti-inflammatory miRNAs that are increased in psoriatic skin. SERPINB2 has been shown to be upregulated in the inflammation and infections. Here we aimed to study the relationship between miR-146a/b and SERPINB2 and to delineate the role of SERPINB2 in association of plaque psoriasis. We report increased SERPINB2 expression in the skin of psoriasis patients, which was in a positive relationship with psoriasis severity and in a negative relationship with miR-146a/b in psoriatic lesions. In cultured keratinocytes, both cellular and secreted SERPINB2 levels were strongly induced in response to IFN-γ and TNF-α. Interestingly, SERPINB2 mRNA was downregulated by IL-17A and the combination of TNF-α and IL-17A at time points when miR-146a was increased. The predicted binding site for miR-146a/b in 3' untranslated region of SERPINB2 revealed no activity in luciferase assay, while siRNA silencing of miR-146a/b direct targets IRAK1 and CARD10 resulted in reduced expression of SERPINB2, suggesting that miR-146a/b indirectly control SERPINB2 expression in the skin. The siRNA silencing of SERPINB2 increased the expression of IL-8, CXCL5 and CCL5 and migration of neutrophils revealing its anti-inflammatory role in keratinocytes. Our data together suggest that SERPINB2 and miR-146a/b are part of disease-related network of molecules that are coordinately regulated and act in controlling the inflammatory responses in psoriatic skin.

Keywords: inflammation; microRNA; protease inhibitor; skin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CARD Signaling Adaptor Proteins / genetics
  • Case-Control Studies
  • Cell Movement
  • Cells, Cultured
  • Chemokine CCL5 / metabolism
  • Chemokine CXCL5 / metabolism
  • Down-Regulation / drug effects
  • Gene Silencing
  • Humans
  • Inflammation / genetics
  • Inflammation / metabolism
  • Interferon-gamma / pharmacology
  • Interleukin-1 Receptor-Associated Kinases / genetics
  • Interleukin-17 / pharmacology
  • Interleukin-8 / metabolism
  • Keratinocytes / metabolism
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Neutrophils / physiology
  • Psoriasis / genetics*
  • Psoriasis / metabolism*
  • RNA, Messenger / metabolism
  • RNA, Small Interfering
  • Severity of Illness Index
  • Tumor Necrosis Factor-alpha / pharmacology
  • Up-Regulation / drug effects

Substances

  • CARD Signaling Adaptor Proteins
  • CARD10 protein, human
  • CCL5 protein, human
  • CXCL5 protein, human
  • CXCL8 protein, human
  • Chemokine CCL5
  • Chemokine CXCL5
  • IL17A protein, human
  • Interleukin-17
  • Interleukin-8
  • MIRN146 microRNA, human
  • MicroRNAs
  • RNA, Messenger
  • RNA, Small Interfering
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma
  • IRAK1 protein, human
  • Interleukin-1 Receptor-Associated Kinases